TScan Therapeutics Inc
TCRX1.695USD
+0.075+4.63%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
95.92MCap. mercado
PérdidaP/E TTM
Más Datos de TScan Therapeutics Inc Compañía
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Información de la empresa
Símbolo de cotizaciónTCRX
Nombre de la empresaTScan Therapeutics Inc
Fecha de salida a bolsaJul 16, 2021
Director ejecutivoMr. Gavin Macbeath, Ph.D.
Número de empleados194
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección830 Winter Street
CiudadWALTHAM
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02451
Teléfono18573999500
Sitio Webhttps://www.tscan.com
Símbolo de cotizaciónTCRX
Fecha de salida a bolsaJul 16, 2021
Director ejecutivoMr. Gavin Macbeath, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.17M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Accionistas
Accionistas
Proporción
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.77%
Hedge Fund
23.77%
Venture Capital
19.29%
Investment Advisor/Hedge Fund
12.62%
Research Firm
2.10%
Individual Investor
0.39%
Bank and Trust
0.35%
Private Equity
0.09%
Pension Fund
0.02%
Other
6.59%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
191
48.87M
93.41%
-296.84K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Adage Capital Management, L.P.
3.50M
6.69%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
4.99%
-57.04K
-2.14%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
Checkpoint Capital L.P.
2.02M
3.86%
+261.66K
+14.90%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Propel Opportunities ETF
2.25%
iShares Health Innovation Active ETF
0.08%
iShares Micro-Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
Ver más
Simplify Propel Opportunities ETF
Proporción2.25%
iShares Health Innovation Active ETF
Proporción0.08%
iShares Micro-Cap ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
